Affinity-purified sHBsAg-based virus-like particles as a platform for foreign mRNA binding
Rattachement africain : pl. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Virus-like particles (VLPs) have long been utilized as immunogens to prevent infectious diseases. Particles derived from the small surface proteins of the hepatitis B virus (sHBsAg) can self-assemble into small, highly immunogenic structures and have been used in human vaccination since the 1980s. Various chimeric sHBsAg VLPs retain their self-assembly ability, even when significant sequence alterations, such as fusions or substitutions, are introduced. This makes them an attractive experimental model and vaccine platform for delivering and presenting foreign epitopes. In the present study, motifs from the hepatitis B virus (HBV) core protein (HBcAg) were introduced into the cytosolic loops of sHBsAg to explore whether these VLPs could acquire the ability to pack mRNA. With one exception, the introduced changes for mRNA binding did not affect ability for self-assemble. A Twin-Strep-tag was added to the N-terminus for more efficient and specific purification. With the exception of one modification, the changes made to allow for mRNA binding did not affect the self-assembly capability of sHBsAg. The recombinant proteins successfully bound mRNAs from various sources. • One-step purification of sHBsAg with a tag results in a high yield of pure protein. •Modified VLPs based on sHBsAg maintain their ability to self-assemble. •The changes introduced into sHBsAg allow for the ability of VLPs to bind mRNAs.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Affinity-purified sHBsAg-based virus-like particles as a platform for foreign mRNA binding
- Date Crossref
- 01/10/2025
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Gdańsk Laboratory of Recombinant Vaccines pays non établi dans la noticeUniversité ou école supérieure
-
Gdańsk Medical University pays non établi dans la noticeUniversité ou école supérieure
-
University of Warsaw Centre of New Technologies pays non établi dans la noticeUniversité ou école supérieure
-
Faculty of Biology Laboratory of Epitranscriptomics pays non établi dans la noticeUniversité ou école supérieure
Laboratory of Recombinant Vaccines — University of Gdańsk, Gdańsk Medical University et Centre of New Technologies — University of Warsaw, avec 1 autre affiliation.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.